Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 14/20 | 0.42 |
| ▸ | SLC16A1 | P53985 | 14/20 | 0.42 |
| ▸ | MCTS1 | Q9ULC4 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383910 | 1.00 | SLC16A3 (0.42) | SLC16A3SLC16A1MCTS1ALDH1A1KMT2A | |
| SCHEMBL4494281 | 0.96 | SLC16A3 (0.43) | SLC16A3SLC16A1MCTS1ALDH1A1KMT2A | |
| SCHEMBL4386165 | 0.96 | SLC16A3 (0.43) | SLC16A3SLC16A1MCTS1ALDH1A1KMT2A | |
| SCHEMBL4386204 | 0.96 | SLC16A3 (0.43) | SLC16A3SLC16A1MCTS1ALDH1A1KMT2A | |
| SCHEMBL4479975 | 0.96 | SLC16A3 (0.43) | SLC16A3SLC16A1MCTS1ALDH1A1KMT2A | |
| SCHEMBL3972569 | 0.92 | SLC16A3 (0.42) | SLC16A3SLC16A1MCTS1ALDH1A1KMT2A | |
| SCHEMBL4375529 | 0.90 | PPARG (0.38) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL4391944 | 0.90 | PPARG (0.38) | SLC16A3SLC16A1MCTS1 | |
| SCHEMBL4384388 | 0.89 | PPARG (0.38) | SLC16A3SLC16A1MCTS1ALDH1A1KMT2A | |
| SCHEMBL1930245 | 0.88 | SLC16A3 (0.43) | SLC16A3SLC16A1MCTS1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789402-B1 | 2-{-3-2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL!-CYCLOHEXYLMETHOXY };-PROPIONIC ACID DERIVATIVES USED AS PPAR LIGANDES (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS) FOR THE TREATMENT OF HYPERLIPIDAEMIE AND DIABETES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-11-18 | — | — | EP | disclosed |